Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Olmesartan medoxomil (OLM) is an ester prodrug of olmesartan (OL) developed to overcome the poor permeability of OL. OLM is an angiotensin receptor blocker and is commonly used to treat hypertension. However, OLM has low water solubility and low bioavailability of 26%. It is understood that OLM is unstable in aqueous media; however, this hydrolysis has not been specifically studied in a way that has produced reliable, publishable data. Previously published analytical methods tend to focus mainly on quantitative measurement of OLM, but not quantitative measurement of OL. The objective of this study was to investigate the solubility and aqueous hydrolysis of OLM in different pH buffers by developing an analytical method for the simultaneous measurement of OLM and OL. A novel HPLC method was developed and validated to simultaneously quantify OLM and OL. The solubility of OLM was pH-dependent 37°C, which could lead to food effects and precipitation of OLM in the small intestine. The aqueous hydrolysis of OLM was rapid and significant and followed the zero-order kinetic model with different hydrolysis rates varying across different pH levels in the order: pH 1.2 < pH 3.5 < pH 4.6 ≈ pH 6. These findings indicate that, in addition to low water solubility, aqueous hydrolysis in the gastrointestinal tract contributes to OLM's low bioavailability. The study emphasizes the importance of fully understanding the solubility and hydrolysis of ester-based prodrugs. Strategies that protect OLM from hydrolysis could have the potential to enhance its bioavailability. Considering ester prodrugs are a key strategy to improve bioavailability, our study in this manuscript is significant for drug formulation development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047831 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0321142 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Multi-way calibration strategies involving excitation-emission data measurements from drug-modulated fluorescence in CdTe quantum dots and AgInS nanocrystals.
Anal Chim Acta
November 2025
The Associated Laboratory for Green Chemistry (LAQV) of the Network of Chemistry and Technology (REQUIMTE) - the Portuguese Research Centre for Sustainable Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313, Porto, Portugal. Electronic address:
Background: When using semiconductor quantum dots (QDs) for single-analyte sensing, recognition is commonly achieved through interactions with capping ligands attached to the QDs surface. These ligands form an organic layer that provides stability in solution and assures selectivity by binding the target analyte via surface functional groups. However, a common analytical challenge arises in the subsequent stage of the QD-based sensing scheme.
View Article and Find Full Text PDFEffectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension.
J Hum Hypertens
September 2025
Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.
This pioneering study investigated the real-life effectiveness of single-pill combination (SPC) antihypertensive therapy in patients with uncontrolled blood pressure (BP) and cardiovascular risk factors. After treatment with olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide for 24 weeks, adults with apparent resistant hypertension had significantly reduced systolic BP and approximately 80% achieved target BP. SPC therapy may improve adherence in patients with pseudo-resistant hypertension and is a potentially effective treatment for resistant hypertension.
View Article and Find Full Text PDFInvestigation of hydrolysis of olmesartan medoxomil in different pH buffers by simultaneously measuring olmesartan medoxomil and olmesartan.
PLoS One
May 2025
Department of Pharmaceutical Sciences, University of North Texas Health Science Center, Fort Worth, Texas, United States of America.
Olmesartan medoxomil (OLM) is an ester prodrug of olmesartan (OL) developed to overcome the poor permeability of OL. OLM is an angiotensin receptor blocker and is commonly used to treat hypertension. However, OLM has low water solubility and low bioavailability of 26%.
View Article and Find Full Text PDFMedoxomil Prodrug Strategies.
J Med Chem
May 2025
Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, 717 Delaware Street, SE, Minneapolis, Minnesota 55414, United States.
Drug discovery campaigns often face biopharmaceutical challenges, some of which can be solved by a prodrug approach. Prodrugs are enzymatically or chemically transformed in vivo to produce active drugs. Among these, medoxomil promoieties have been judiciously employed in multiple drug discovery campaigns, leading to three prodrugs gaining FDA approval: azilsartan medoxomil (), olmesartan medoxomil (), and ceftobiprole medocaril (), and one approval in Japan: prulifloxacin ().
View Article and Find Full Text PDFGastroretentive microballoons of olmesartan medoxomil: formulation and evaluation.
Ther Deliv
March 2025
Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, India.
Background: Olmesartan medoxomil, classified as BCS class II due to its poor water solubility, exhibits a low oral bioavailability of 28.6%.
Materials And Methods: Microballoons of Olmesartan medoxomil were formulated using the ionotropic gelation technique and subjected to various evaluation parameters.